AU Patent

AU2017332771A1 — Dose adjustment

Assigned to AbbVie Inc · Expires 2019-04-04 · 7y expired

What this patent protects

This application features dose adjustment for drugs co-administered with glecaprevir and pibrentasvir.

USPTO Abstract

This application features dose adjustment for drugs co-administered with glecaprevir and pibrentasvir.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017332771A1
Jurisdiction
AU
Classification
—
Expires
2019-04-04
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.